Brought to you by 
Acerus Buys Back All Remaining U.S. Rights for NATESTO From Aytu
01 Apr 2021
Executive Summary
Aytu BioScience Inc. licensed exclusive US marketing rights to Acerus Pharmaceuticals Corp.'s Natesto (testosterone), a nasal gel FDA-approved for testosterone replacement therapy in adult males diagnosed with hypogonadism.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
- Topical Delivery
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acerus Buys Back All Remaining U.S. Rights for NATESTO From Aytu
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice